Pharmacokinetics of sunitinib in an obese patient with a GIST
Authors:
Open Access
- 19 January 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (3) , 599-600
Abstract
Sunitinib is a potent inhibitor of a variety of receptor tyrosine kinases including vascular endothelial growth factor receptors (1, 2 and 3), fetal liver tyrosine kinase receptor 3, stem-cell factor receptor (KIT), platelet-derived growth factor receptors (alpha and beta) and colony-stimulating factor-1 receptor. It is approved for the treatment of imatinib-resistant gastrointestinal stromal tumours (GISTs) and metastatic renal cell cancer. Data about the pharmacokinetics of sunitinib in seriously obese patients are lacking. We here report the pharmacokinetic data of such an obese GIST patient treated with sunitinib.Keywords
This publication has 3 references indexed in Scilit:
- Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approachJournal of Clinical Oncology, 2007
- A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCancer Chemotherapy and Pharmacology, 2007
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006